Development of novel cancer immunotherapy based on comprehensive control of effector regulatory T-cells

2016 Fiscal Year Final Research Report

• Project/Area Number: 26430173
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Aichi Medical University
• Principal Investigator: Suzuki Susumu 愛知医科大学, 医学部, 准教授 (70518422)
• Co-Investigator(Renkei-kenkyūsha): Ueda Ryuzo 愛知医科大学, 医学部 腫瘍免疫寄附講座, 教授 (20142169)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: エフェクター制御性T細胞 / CCケモカイン受容体4(CCR4) / 細胞傷害性T細胞 / 免疫不全マウス / 腫瘍免疫増強

Outline of Final Research Achievements

Although elimination regulatory T-cell（Treg）by anti-CCR4 antibody was clearly observed, and the reactivation of immunity with the elimination of Tregs was partially clarified in in vitro experiment, the expected results could not be achieved because human Tregs were not almost infiltrated into cancer tissue generated in mouse. However, it is expected that the spread to mouse model for human cancer immunotherapy using immune checkpoint inhibitors etc. because human T-cells were remarkably infiltrated into the tissue and the cancer necrosis was observed. And, CCR4+Treg subset analysis in human cancer tissues was performed. it was observed that infiltration of CCR4+Treg subset is related with pathological stage and recurrence which suggest significance of cancer therapy targeting CCR4.

Free Research Field

腫瘍免疫